Aug 2026· Scientific Reports· Vol 16· 0 citations· 40 references
Medicine
TL;DR
DZ-ART1 represents a new class of anti-cancer therapeutics that uniquely combines diagnostic imaging and cancer cell organelle-specific targeting and increased the lethal effect of chemotherapies in vitro and in vivo.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. In this paper, we present DZ-ART1, a first-in-class, dual-function therapeutic. This innovative agent is composed of a tumor-targeting heptamethine carbocyanine dye conjugated to artemisinin (ART). Near-infrared imaging demonstrated precise tumor localization of DZ-ART1 in mice. DZ-ART1 accumulated 5- to 10-fold more in cancer cells compared to normal cells. DZ-ART1 significantly decreased the survival of eight PDAC cell lines with little effect on normal cells. It increased the lethal effect of chemotherapies in vitro and in vivo. Functional assays confirmed DZ-ART1’s ability to disrupt mitochondrial bioenergetics, deplete ATP, and induce reactive oxygen species production. Mitochondrial depletion of cancer cells decreased DZ-ART1 uptake and cytotoxicity, highlighting its mechanistically unique, mitochondria-dependent action. Transcriptomic profiling revealed DZ-ART1’s broad reprogramming of PDAC pathways related to cell survival, cancer stemness, and metastasis. In three rigorously validated preclinical models — Krasþ/LSLG12D;Trp53þ/LSLR172H;Pdx-1-Cre (KPC) transgenic, syngeneic, and patient-derived xenografts (PDX) — DZ-ART1 markedly suppressed tumor growth and metastasis and prolonged survival, all without toxicity to normal tissues. DZ-ART1 represents a new class of anti-cancer therapeutics that uniquely combines diagnostic imaging and cancer cell organelle-specific targeting.
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, largely due to rapid development of resistance to standard chemotherapies such as gemcitabine. MICAL2 is a redox-dependent regulator of actin dynamics that is overexpressed in PDAC, but its role in therapeutic resistance remains poorly un...
Ponmathi Panneerpandian, Kevin Christian Montecillo Gulay, M. Macdonald et al.· Cancer Research· 0 citations
EGFR is an oncogenic factor highly expressed in multiple tumor types. While previous research has primarily focused on plasma membrane-localized EGFR, the role of its mitochondrial localization (mitoEGFR) in breast cancer remains poorly understood. This study reveals that EGFR is enriched in mitochondria in triple-ne...
Yuan-Zhen Li, Si-Yuan Yang, Xu Yang et al.· Cell Death & Disease· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal and metastatic malignancy, with standard-of-care treatments, such as gemcitabine/nab-paclitaxel (GnP) offering limited improvement for patients with advanced disease. We and others have shown that co-targeting key factors in combination with chemotherapy...
Shona Ritchie, Victoria M. Tyma, Shanna Hafiz et al.· Cancer Research· 0 citations
It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.
Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al.· Cancer Research· 0 citations
Chemotherapy remains the mainstay treatment of many solid cancers; however, resistance and recurrence compromise patient outcomes. We investigated chemotherapy resistance mechanisms in Triple Negative Breast Cancer (TNBC) by examining cells that survive chemotherapy-induced apoptotic caspase activation. Using a biose...
R. Hausman, Wells S. Brown, S. Awrey et al.· Cell Death & Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.